Your UK Buyer Probably Cannot Legally Import Your Flower

A UK distributor tells you they hold a Wholesale Dealer's Licence and import cannabis regularly. Everything sounds ready. It usually is not, and the reason is a single line in UK licensing that most commercial conversations never reach.

A WDA(H) permits import of unlicensed cannabis-based products for medicinal use from an EEA member state — the EU plus Norway, Iceland and Liechtenstein. It does not permit import from a third country. For material originating outside the EEA — Thailand, Australia, Canada, the United States — the importer needs a Manufacturer's "Specials" licence, an MS licence, which is a manufacturing authorisation rather than a wholesaling one.

So a buyer holding only a WDA(H) can lawfully import Portuguese flower and cannot lawfully import yours. They are not misleading you. Their licence genuinely does authorise import; it just does not authorise import from where you are.

The question that belongs in the first conversation

Not "can you import?" — they will say yes, truthfully.

"Do you hold a Manufacturer's Specials licence, or a WDA(H)? And has your route taken product from a non-EEA origin before?"

An MS licence holder can bring in and release finished product from a GMP-certified facility anywhere, EU or not, and distribute to UK pharmacies. A WDA(H) holder needs the goods to have entered the EEA first and been released there. Those are different businesses with different partners, and knowing which one you are talking to changes everything that follows: the price basis, the timeline, and whether a third party is required at all.

We have watched suppliers spend months on UK conversations that could not have concluded, because nobody asked this in week one.

Why the EU-GMP converter route dominates

This licensing line explains a market pattern that otherwise looks like mere habit. UK private clinics rely heavily on imported GMP-certified flower, predominantly from Portugal, Australia and Canada. Most distributors serving them hold wholesaling authorisations, not manufacturing ones. Their processes are built around material that is already GMP-released when it reaches them.

For a GACP-only origin outside the EEA, that leaves the shape of the deal fairly determined: the GMP step happens before the UK border, performed by someone who holds the authorisation to perform it. The question is not whether a third party is involved, but which one and on what terms.

Three workable structures, and who holds the GMP obligation

Through an EU-GMP converter. Thai GACP flower ships to a certified processor in the EU, is released to EU-GMP there, and moves onward to the UK as GMP product. The most common shape, and the one we consider most practical for Thai origin. The converter holds the obligation; you hold the cultivation file that lets their qualified person release against it.

Through a UK manufacturer. The importer or a contracted manufacturer holds MHRA manufacturing authorisation and performs release in the UK. Fewer parties can do this, and those who can are selective about origin — which is a compliment to be earned, not a formality.

Direct supply of unlicensed product, where the specific clinical route permits it. Narrow, and dependent entirely on the importer's own authorisations rather than on anything an exporter can arrange.

A producer who tells a UK buyer "we can supply you directly" without naming which of these three applies has not thought about the question.

The calendar has a floor nobody can compress

Two timing facts sit on top of whichever structure applies.

Twenty-eight days' notification. For unlicensed cannabis-based products for medicinal use — the category most UK prescriptions fall into — the importer must notify the MHRA at least 28 days before the intended date of import, with supporting documentation for assessment.

Per-shipment Home Office licensing. Import and export of cannabis require Home Office controlled-drug licences issued for each shipment, alongside the corresponding INCB authorisations. Per-shipment is the standard rhythm, not an exception, and it is a recognised source of supply gaps for UK patients.

Neither is an exporter's obligation. Both are reasons a delivery date promised at contract signature is a guess. The UK floor is four weeks before anything moves, and it does not shorten for urgency.

What we can offer a UK-facing partner today

EU-GACP: our Sabai Sabai Farm site in Chanthaburi holds a Control Union GAP & GACP declaration to the WHO and EMA guidelines (valid to September 2027) and Thai DTAM Cannabis GACP certification (TH-GACP 87/2568, 4,104 m², valid to September 2028). We are not a GMP manufacturer.

Our flower has been imported by clients into Germany, Portugal and Switzerland, and our samples have been tested against Australia's TGO 93 parameters. We have not supplied the United Kingdom. We say so plainly, because a first UK route would be built together with a partner holding the GMP step — not claimed as experience we do not have.

What we bring is the upstream half, done properly: consistent cultivars from in-house phenohunting, fifteen flowering rooms with installed capacity around 900 kg per month, hand-trimmed non-irradiated flower, and batch traceability from room and harvest through to the packed batch.

Non-irradiated flower, and why it has to be settled early

Irradiation is routine in several supply chains feeding the UK. We do not irradiate: irradiation measurably reduces terpene content.

For a partner building a premium proposition that is a differentiator worth pricing. But it is a specification decision that must be made in the first conversation, not the last. If the eventual UK channel requires irradiated material, the treatment happens somewhere along the chain, someone pays for it, and the batch that arrives is no longer the batch that was tested at origin — the certificate on file describes material that no longer exists in that form.

Before your next UK call

• Ask which licence they hold: MS or WDA(H). Everything follows from the answer.
• Ask whether their route has carried non-EEA origin material before, and through whom.
• Agree the irradiation question before the specification, not after.
• Build the schedule from the 28-day notification and per-shipment licensing, not from the calendar.

For supply discussions: [email protected]